-
1
-
2
SOCS2 inhibits the tumorigenesis of GISTs and increases the sensitivity of GISTs to imatinib by suppression of KIT activation
Published 2025-02-01Subjects: Get full text
Article -
3
Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data
Published 2024-09-01Subjects: Get full text
Article